Thus, therapeutic potential of counteracting hyper PRC2 activity, such as EZH2 inhibitors, in cancer has been under intensive investigation for the past decades 14, whereas strategies targeting KDM6 in cancer treatment that just emerged in recent few years surprisingly have already demonstrated promising effect against various cancer types, including glioma 15-17, neuroblastoma 18, acute myeloid leukemia 19, and castration resistant prostate cancer 20. Here, EZH2 is linked to cancer.